Skip to main content

Day: November 22, 2022

CinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor Conferences

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November:Event: Piper Sandler 34th Annual Healthcare ConferenceDate: November 29 – December 1, 2022Location: Lotte New York Palace in New York, New YorkPresentation: Tuesday, November 29, 2022 at 1:30pm ESTWebcast: https://event.webcasts.com/starthere.jsp?ei=1585686&tp_key=3261cabcd6   Event: Evercore ISI 5th Annual HealthCONx ConferenceDate: November 30 – December 1, 2022Location: VirtualPresentation: Thursday, December 1, 2022 at 3:30pm ESTWebcast: https://wsw.com/webcast/evercore29/cinc/2336910The CinCor management team will participate in one-on-one investor meetings during these events. Investors interested...

Continue reading

Fluence Energy, Inc. Announces Fourth Quarter and Fiscal Year 2022 Earnings Release Date, Conference Call and Webcast

ARLINGTON, Va., Nov. 22, 2022 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), announced today that it will report earnings for the fourth quarter and fiscal year ended September 30, 2022 on Monday, December 12th, 2022, after market close. The Company will conduct a teleconference starting at 8:30 a.m. EDT on Tuesday, December 13th, 2022, to discuss the results. To participate, analysts are required to register by clicking Fluence Energy Q4 Earnings Call Registration Link. Once registered, analysts will be issued a unique PIN number and dial-in number. Analysts are encouraged to register at least 15 minutes before the scheduled start time. General audience participants, and non-analysts are encouraged to join the teleconference in a listen-only mode at: Listen-Only Mode – Webcast Link,...

Continue reading

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Key Points:Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001 Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of children or adults with SR-aGVHD who received best available therapy (BAT) or the only approved agent in adults1-4 These results reaffirm the potential significance of remestemcel-L as a life-saving therapy for children with SR-aGVHD These long-term survival outcomes are a key component of the Biologics License Application (BLA) resubmission to the United States Food and Drug Administration (FDA)NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line long-term survival...

Continue reading

Washington Water Service Completes Acquisition of Driftwood Valley Water

GIG HARBOR, Wash., Nov. 22, 2022 (GLOBE NEWSWIRE) — Washington Water Service (Washington Water), a subsidiary of California Water Service Group (Group), announced today that it has completed the acquisition of Driftwood Valley Association’s water system assets. Washington Water will now provide water utility service to Driftwood Valley Homeowner Association’s 62 customers in Yelm, Wash. As part of the acquisition, Washington Water also expects to provide service to new customers in the association as its 21 empty lots are developed. Washington Water plans to continue investing in local water system infrastructure to help maintain a reliable supply of safe, clean water flowing to customers for their everyday needs and to firefighters for emergencies. “We welcome Driftwood Valley customers to the Washington Water family, and we look...

Continue reading

Monument Mining Announces Results of Annual General and Special Meeting of Shareholders

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) (“Monument” or the “Company”) is pleased to announce the results from its Annual General and Special Meeting of shareholders held on November 22, 2022 in Vancouver, B.C. Resolutions tabled at the Annual General and Special Meeting as proposed in the Information Circular dated on October 18, 2022 were all passed with more than 90% “For” for each and overwhelming participation, including: a special resolution authorizing and approving the continuance of the Company out of the federal jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia); appointing Grant Thornton LLP as auditors; and fixing the number...

Continue reading

UMH PROPERTIES, INC. COMPLETES ACQUISITION OF OHIO MANUFACTURED HOME COMMUNITY

FREEHOLD, NJ, Nov. 22, 2022 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) closed on the acquisition of a manufactured home community, located in Canton, Ohio, for a total purchase price of $19.1 million. This community contains 321 developed homesites, of which 77% are occupied. It is situated on approximately 170 acres. Samuel A. Landy, President and Chief Executive Officer, commented, “We are pleased to complete the acquisition of Fohl Village. This is a high-quality community located in a strong market that we have historically performed well in. This community is in good condition, with limited deferred maintenance and capital improvements, and with strong upside through the infill of vacant sites. We plan on implementing our rental home business model which will improve operating results and increase the property value. “We...

Continue reading

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022

Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for approval of remestemcel-L in the treatment of children with SR-aGVHD NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended September 30, 2022 and provided an update on upcoming milestones. “The substantial and durable long-term survival over four years we have reported today in children with SR-aGVHD treated with remestemcel-L in our Phase 3 trial underscore the many lives that could potentially be saved by making...

Continue reading

Brookfield Reinsurance Announces Record Date for the Special Distribution

BROOKFIELD, NEWS, Nov. 22, 2022 (GLOBE NEWSWIRE) — Brookfield Reinsurance (NYSE, TSX: BAMR) (“Brookfield Reinsurance” or the “Company”) today announced that it has set a distribution record date of December 2, 2022 (the “Record Date”) for the previously announced special distribution (the “Special Distribution”) of shares of Brookfield Asset Management Ltd. (the “Manager shares”) to the holders of its class A exchangeable limited voting shares (“Brookfield Reinsurance Class A Shares”) and class B limited voting shares (“Brookfield Reinsurance Class B Shares”). Background – Brookfield Arrangement Brookfield Asset Management Inc. (“Brookfield”) announced earlier today that it has received all material approvals for the previously announced transaction for the public listing and distribution of a 25% interest in its asset management...

Continue reading

Fountain Asset Corp. Announces Its Financial Results for the Quarter Ended September 30, 2022

TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) — Fountain Asset Corp. (TSXV:FA) (“Fountain” or the “Company”) would like to announce its financial results for the three months ended September 30, 2022 (“Q3/22”). Highlights from the three months ended September 30, 2022:Adjusted net asset value (“ANAV”) of $17.80 million ($0.29 per share) at September 30, 2022 compared to $17.63 million ($0.28 per share) at June 30, 2022, representing an increase of 3.6% quarter over quarter on a per share basis. ANAV reflects the net asset value plus the amount of available tax loss pools; Net comprehensive income of $0.11 million compared to net comprehensive loss of $0.91 million for three months ended September 30, 2021 (“Q3/21”); Total revenue from investment activity was $0.26 million compared to total revenue loss of $0.59 million for Q3/21; Net...

Continue reading

Helium Evolution Announces Filing of Third Quarter 2022 Financial and Operating Results

Strong balance sheet, acceleration of NAH drilling program and continued internal technical work drive HEVI closer to the ultimate goal of helium production CALGARY, Alberta, Nov. 22, 2022 (GLOBE NEWSWIRE) — Helium Evolution Incorporated (TSXV:HEVI) (“HEVI” or the “Company“), a Canadian-based helium exploration and production company focused on developing assets in southern Saskatchewan, today announced the filing of our unaudited financial results for the three and nine- month periods ended September 30, 2022, along with a corporate update on activities that have occurred subsequent to the end of the period. For complete details of the condensed interim consolidated financial statements and the associated management’s discussion and analysis, please refer to the Company’s filing on SEDAR (www.sedar.com). Three...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.